- Home
- INZY vs CSPI Comparison
INZY vs CSPI Comparison
Compare INZY & CSPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- CSPI
- Stock Information
- Founded
- INZY 2015
- CSPI 1968
- Country
- INZY United States
- CSPI United States
- Employees
- INZY N/A
- CSPI N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- CSPI EDP Services
- Sector
- INZY Health Care
- CSPI Technology
- Exchange
- INZY Nasdaq
- CSPI Nasdaq
- Market Cap
- INZY 188.2M
- CSPI 174.4M
- IPO Year
- INZY 2020
- CSPI 1987
- Fundamental
- Price
- INZY $1.40
- CSPI $19.29
- Analyst Decision
- INZY Strong Buy
- CSPI
- Analyst Count
- INZY 8
- CSPI 0
- Target Price
- INZY $17.75
- CSPI N/A
- AVG Volume (30 Days)
- INZY 1.0M
- CSPI 28.7K
- Earning Date
- INZY 03-11-2025
- CSPI 02-12-2025
- Dividend Yield
- INZY N/A
- CSPI 0.64%
- EPS Growth
- INZY N/A
- CSPI N/A
- EPS
- INZY N/A
- CSPI N/A
- Revenue
- INZY N/A
- CSPI $55,219,000.00
- Revenue This Year
- INZY N/A
- CSPI N/A
- Revenue Next Year
- INZY N/A
- CSPI N/A
- P/E Ratio
- INZY N/A
- CSPI N/A
- Revenue Growth
- INZY N/A
- CSPI N/A
- 52 Week Low
- INZY $1.24
- CSPI $10.06
- 52 Week High
- INZY $7.80
- CSPI $29.93
- Technical
- Relative Strength Index (RSI)
- INZY 31.52
- CSPI 56.78
- Support Level
- INZY $1.35
- CSPI $15.67
- Resistance Level
- INZY $1.45
- CSPI $20.49
- Average True Range (ATR)
- INZY 0.12
- CSPI 1.07
- MACD
- INZY 0.04
- CSPI 0.22
- Stochastic Oscillator
- INZY 43.42
- CSPI 57.25
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About CSPI CSP Inc.
CSP Inc along with its subsidiaries develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments namely Technology Solutions, where the company focus on value-added reseller integrated solutions including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company design, manufacture and deliver products and services to customers that require specialized cyber security services, networking and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates its maximum revenue from the Americas.